Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Interleukin-13 Receptor Subunit Alpha-2 (IL-13Rα2)

  • Riaz Jannoo
  • Venkateswarlu Kanamarlapudi
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101987

Synonyms

Historical Background

Interleukin (IL)-13 is an immune regulatory cytokine that plays an important role in allergy and atopic diseases (Hershey 2003; Karp 2004). It has two receptors, IL-13 receptor (IL-13R)α1 and IL-13Rα2. IL-13Rα1 monomer binds IL-13 with low affinity and mediates IL-13 cellular functions by pairing with IL-4 receptor (IL-4R)α. The IL-13 binding to IL-13Rα1/IL-4Rα heterodimer leads to activation of signal transducer and activator transcription (STAT)6 by Janus kinases (JAKs) (Miloux et al. 1997). IL-13Rα2 binds to IL-13 with high affinity but doesn’t mediate IL-13 cellular functions due to having a short cytoplasmic tail and no signaling motifs in it (Donaldson et al. 1998). The cDNA for IL-13Rα2 has first been isolated from human renal carcinoma cell lines. In 1996,...

This is a preview of subscription content, log in to check access.

References

  1. Andrews AL, Nordgren IK, Campbell-Harding G, Holloway JW, Holgate ST, Davies DE, Tavassoli A. The association of the cytoplasmic domains of interleukin 4 receptor alpha and interleukin 13 receptor alpha 2 regulates interleukin 4 signaling. Mol BioSyst. 2013;9:3009–14.CrossRefPubMedGoogle Scholar
  2. Arima K, Sato K, Tanaka G, Kanaji S, Terada T, Honjo E, Kuroki R, Matsuo Y, Izuhara K. Characterization of the interaction between interleukin-13 and interleukin-13 receptors. J Biol Chem. 2005;280:24915–22.CrossRefPubMedGoogle Scholar
  3. Badalyan V, Thompson R, Addo K, Borthwick LA, Fisher AJ, Ort T, Myers TG, Wynn TA, Ramalingam TR. TNF-alpha/IL-17 synergy inhibits IL-13 bioactivity via IL-13Ralpha2 induction. J Allergy Clin Immunol. 2014;134:975–8 .e975PubMedPubMedCentralCrossRefGoogle Scholar
  4. Bartolomé RA, García-Palmero I, Torres S, López-Lucendo M, Balyasnikova IV, Casal JI. IL13 receptor α2 signaling requires a scaffold protein, FAM120A, to activate the FAK and PI3K pathways in colon cancer metastasis. Cancer Res. 2015;75:2434–44.CrossRefPubMedGoogle Scholar
  5. Caput D, Laurent P, Kaghad M, Lelias J-M, Lefort S, Vita N, Ferrara P. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain. J Biol Chem. 1996;271:16921–6.CrossRefPubMedGoogle Scholar
  6. Chen W, Sivaprasad U, Tabata Y, Gibson AM, Stier MT, Finkelman FD, Hershey GKK. IL-13Rα2 membrane and soluble isoforms differ in humans and mice. J Immunol. 2009;183:7870–6.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Investig. 1999;104:777–85.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Cho WK, Lee CM, Kang MJ, Huang Y, Giordano FJ, Lee PJ, Trow TK, Homer RJ, Sessa WC, Elias JA, Lee CG. IL-13 receptor alpha2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2013;304:L112–24.CrossRefPubMedGoogle Scholar
  9. Daines MO, Hershey GKK. A novel mechanism by which interferon-γ can regulate interleukin (IL)-13 responses: evidence for intracellular stores of IL-13 receptor α-2 and their rapid mobilization by interferon-γ. J Biol Chem. 2002;277:10387–93.CrossRefPubMedGoogle Scholar
  10. Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O’Hara RM, Beier DR, Turner KJ, Wood CR, Collins M. The murine IL-13 receptor α2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol. 1998;161:2317–24.PubMedGoogle Scholar
  11. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13[alpha]2 receptor is involved in induction of TGF-[beta]1 production and fibrosis. Nat Med. 2006a;12:99–106.CrossRefPubMedGoogle Scholar
  12. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006b;12:99–106.CrossRefPubMedGoogle Scholar
  13. Fichtner–Feigl S, Young CA, Kitani A, Geissler EK, Schlitt HJ, Strober W. IL-13 signaling via IL-13Rα2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology. 2008;135: 2003–13.e2007.CrossRefGoogle Scholar
  14. Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res. 2009;69:8678–85.CrossRefPubMedGoogle Scholar
  15. Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer. 2012;131:344–56.CrossRefPubMedGoogle Scholar
  16. Gonzalez-Moreno O, Calvo A, Joshi BH, Abasolo I, Leland P, Wang Z, Montuenga L, Puri RK, Green JE. Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. Int J Cancer. 2005;114:870–8.CrossRefPubMedGoogle Scholar
  17. Granel B, Allanore Y, Chevillard C, Arnaud V, Marquet S, Weiller P-J, Durand J-M, Harlé J-R, Grange C, Frances Y, Berbis P, Gaudart J, de Micco P, Kahan A, Dessein A. IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol. 2006;33:2015–9.PubMedGoogle Scholar
  18. Guo J, Apiou F, Mellerin M-P, Lebeau B, Jacques Y, Minvielle S. Chromosome mapping and expression of the human interleukin-13 receptor. Genomics. 1997;42:141–5.CrossRefPubMedGoogle Scholar
  19. He CH, Lee CG, Dela Cruz CS, Lee C-M, Zhou Y, Ahangari F, Ma B, Herzog EL, Rosenberg SA, Li Y, Nour AM, Parikh CR, Schmidt I, Modis Y, Cantley L, Elias JA. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep. 2013;4:830–41.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Hershey GKK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003;111:677–90.CrossRefPubMedGoogle Scholar
  21. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK. Expression of interleukin-13 receptor α2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res. 2007;67:7983–6.CrossRefPubMedGoogle Scholar
  22. Karp MW. Interleukin-13 in asthma pathogenesis. Curr Allergy Asthma Rep. 2004;4:123–31.CrossRefGoogle Scholar
  23. Kasaian MT, Raible D, Marquette K, Cook TA, Zhou S, Tan X-Y, Tchistiakova L. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2. J Immunol. 2011;187:561–9.CrossRefPubMedGoogle Scholar
  24. Kawakami K, Takeshita F, Puri RK. Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain. J Biol Chem. 2001a;276:25114–20.CrossRefPubMedGoogle Scholar
  25. Kawakami K, Takeshita F, Puri RK. Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor α2 chain. J Biol Chem. 2001b;276:25114–20.CrossRefPubMedGoogle Scholar
  26. Kawakami M, Kawakami K, Kasperbauer JL, Hinkley LL, Tsukuda M, Strome SE, Puri RK. Interleukin-13 receptor α2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res. 2003;9:6381–8.PubMedGoogle Scholar
  27. Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK. Characterization of a novel human tumor antigen interleukin-13 receptor α2 chain. Cancer Res. 2006;66:4434–42.CrossRefPubMedGoogle Scholar
  28. Kioi M, Kawakami K, Puri RK. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and pseudomonas exotoxin. Clin Cancer Res. 2004;10:6231–8.CrossRefPubMedGoogle Scholar
  29. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer. 2006a;107:1407–18.CrossRefPubMedGoogle Scholar
  30. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK. Interleukin-13 receptor α2 chain. Cancer. 2006b;107:1407–18.CrossRefPubMedGoogle Scholar
  31. Kioi M, Seetharam S, Puri RK. N-linked glycosylation of IL-13Rα2 is essential for optimal IL-13 inhibitory activity. FASEB J. 2006c;20:2378–80.CrossRefPubMedGoogle Scholar
  32. Lee C-M, He CH, Nour AM, Zhou Y, Ma B, Park JW, Kim KH, Cruz CD, Sharma L, Nasr ML, Modis Y, Lee CG, Elias JA. IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses. Nat Commun. 2016;7:12752.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Rα2. Structure (London, England: 1993). 2010;18:332–42.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Mentink-Kane MM, Cheever AW, Thompson RW, Hari DM, Kabatereine NB, Vennervald BJ, Ouma JH, Mwatha JK, Jones FM, Donaldson DD, Grusby MJ, Dunne DW, Wynn TA. IL-13 receptor α 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci U S A. 2004;101:586–90.CrossRefPubMedGoogle Scholar
  35. Miloux B, Laurent P, Bonnin O, Lupker J, Caput D, Vita N, Ferrara P. Cloning of the human IL-13Rα1 chain and reconstitution with the IL-4Rα of a functional IL-4/IL-13 receptor complex. FEBS Lett. 1997;401:163–6.CrossRefPubMedGoogle Scholar
  36. Miyoshi M, Horiuchi H, Fukushima Y, Matsuda H, Furusawa S. Cloning of the chicken interleukin-13 receptor α2 gene and production of a specific monoclonal antibody. Dev Comp Immunol. 2007;31:394–406.CrossRefPubMedGoogle Scholar
  37. Orchansky PL, Kwan R, Lee F, Schrader JW. Characterization of the cytoplasmic domain of interleukin-13 receptor-α. J Biol Chem. 1999;274:20818–25.CrossRefPubMedGoogle Scholar
  38. Papageorgis P, Ozturk S, Lambert AW, Neophytou CM, Tzatsos A, Wong CK, Thiagalingam S, Constantinou AI. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis. Breast Cancer Res. 2015;17:98.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Plante S, Semlali A, Joubert P, Bissonnette É, Laviolette M, Hamid Q, Chakir J. Mast cells regulate procollagen I (α1) production by bronchial fibroblasts derived from subjects with asthma through IL-4/IL-4δ2 ratio. J Allergy Clin Immunol. 2006;117:1321–7.CrossRefPubMedGoogle Scholar
  40. Puri R, Leland P, Obiri N, Husain S, Kreitman R, Haas G, Pastan I, Debinski W. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of pseudomonas exotoxin A (PE38QQR). Blood. 1996;87:4333–9.PubMedGoogle Scholar
  41. Tabata Y, Khurana Hershey GK. IL-13 receptor isoforms: breaking through the complexity. Curr Allergy Asthma Rep. 2007;7:338–45.CrossRefPubMedGoogle Scholar
  42. Warren S, Atsushi K, Stefan F-F, Ivan JF. The signaling function of the IL-13Rα2 receptor in the development of gastrointestinal fibrosis and cancer surveillance. Curr Mol Med. 2009;9:740–50.CrossRefGoogle Scholar
  43. Wood N, Whitters MJ, Jacobson BA, Witek J, Sypek JP, Kasaian M, Eppihimer MJ, Unger M, Tanaka T, Goldman SJ, Collins M, Donaldson DD, Grusby MJ. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor α2. J Exp Med. 2003;197:703–9.PubMedPubMedCentralCrossRefGoogle Scholar
  44. Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor α2, EphA2, and fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res. 2008;14:199–208.CrossRefPubMedGoogle Scholar
  45. Zhang J-G, Hilton DJ, Willson TA, McFarlane C, Roberts BA, Moritz RL, Simpson RJ, Alexander WS, Metcalf D, Nicola NA. Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein: evidence that it is distinct from the cloned IL-13 receptor and IL-4 receptor α-chains. J Biol Chem. 1997;272:9474–80.CrossRefPubMedGoogle Scholar
  46. Zhao Z, Wang L, Xu W. IL-13Ralpha2 mediates PNR-induced migration and metastasis in ERalpha-negative breast cancer. Oncogene. 2014;34:1596.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Zhao Z, Wang L, Xu W. IL-13Rα2 mediates PNR-induced migration and metastasis in ERα-negative breast cancer. Oncogene. 2015;34:1596–607.CrossRefPubMedGoogle Scholar
  48. Zheng T, Zhu Z, Liu W, Lee CG, Chen Q, Homer RJ, Elias JA. Cytokine regulation of IL-13Rα2 and IL-13Rα1 in vivo and in vitro. J Allergy Clin Immunol. 2003;111:720–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Institute of Life Science 1, School of MedicineSwansea UniversitySwanseaUK